Palliative Splenectomy in Myelofibrosis with Myeloid Metaplasia

References

• Adamson J. W., Fialkow P. J. The pathogenesis of myeloproliferative syndromes. British Journal of Haematology 1978; 38: 299–303
   PubMed Web of Science ®Google Scholar
• Dameshek W. Some speculations on the myeloproliferative syndrome (editorial). Blood 1951; 6: 372–375
   PubMed Web of Science ®Google Scholar
• Gilbert H. S. The spectrum of myeloproliferative disorders. The Medical Clinics of North America 1973; 57: 355–393
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine 2000; 342: 1255–1265
   PubMed Web of Science ®Google Scholar
• Thiele J., Chen Y. S., Kvasnicka H. M., Diehl V., Fischer R. Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosisa histomorphometric study on sequential trephine biopsies. Leukemia & Lymphoma 1994; 14: 163–169
   PubMed Web of Science ®Google Scholar
• Kvasnicka H. M., Thiele J., Regn C., Zankovich R., Diehl V., Fischer R. Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis. Annals of Hematology 1999; 78: 65–72
   PubMed Web of Science ®Google Scholar
• Wolf B. C., Banks P. M., Mann R. B., Neiman R. S. Splenic hematopoiesis in polycythemia vera. A morphologic and immunohistologic study. American Journal of Clinical Pathology 1988; 89: 69–75
   PubMed Web of Science ®Google Scholar
• Dupriez B., Morel P., Demory J. L., Lai J. L., Simon M., Plantier I., Haulers F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018
   PubMed Web of Science ®Google Scholar
• Cervantes F., Pereira A., Esteve J., Rafel M., Cobo R, Rozman C., Montserrat E. Identification of short-lived and long-lived patients at presentation of idiopathic myelofibrosis. British Journal of Haematology 1997; 97: 635–640
   PubMed Web of Science ®Google Scholar
• Guardiola P., Anderson J. E., Bandini G., Cervantes F., Runde V., Arcese W., Bacigalupo A., Przepiorka D., O'Donnell M. R., Polchi P., Buzyn A., Sutton L., Cazals-Hatem D., Sale G., de Witte T, Deeg H. J., Gluckman E. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societé Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838
   PubMed Web of Science ®Google Scholar
• Mesa R. A., Silverstein M. N., Jacobsen S. J., Wollan P. C., Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. American Journal of Hematology 1999; 61: 10–15
   PubMed Web of Science ®Google Scholar
• Besa E. C., Nowell P. C., Geller N. L., Gardner F. H. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49: 308–313
   PubMed Web of Science ®Google Scholar
• Gilbert H. S. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83: 1205–1213
   PubMed Web of Science ®Google Scholar
• Levy V., Bourgarit A., Delmer A., Legrand O., Baudard M., Rio B., Zittoun R. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. American Journal of Hematology 1996; 53: 239–241
   PubMed Web of Science ®Google Scholar
• Sacchi S. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leukemia & Lymphoma 1995; 19: 13–20
   PubMed Web of Science ®Google Scholar
• Wadenvik H., Kutti J. The spleen and pooling of blood cells. European Journal of Haematology 1988; 41: 1–5
   PubMed Web of Science ®Google Scholar
• Schwartz S. Physiology of the spleen and the role of splenectomy in the hematologic disorders. Surgical Care II, R. E. Condon, J. J. DeCosse. Lea & Febiger, Philadelphia 1985; 118
   Google Scholar
• Chapman W. C., Newman M. Disorders of the spleen. Wintrobe's Clinical Hematology, G.R. Lee, J. Foerster, J. Lukens, F. Paraskevas, J. P. Greer, G. M. Rodgers. Williams & Wilkins, Baltimore 1999; 2: 1969–1989
   Google Scholar
• Wilkins B. S., Green A., Wild A. E., Jones D. B. Extramedullary haemopoiesis in fetal and adult human spleen: a quantitative immunohistological study. Histopathology 1994; 24: 241–247
   PubMed Web of Science ®Google Scholar
• Ward H. P., Block M. H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971; 50: 357–420
   PubMed Web of Science ®Google Scholar
• Zhang B., Lewis S. M. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. European Journal of Haematology 1989; 43: 63–66
   PubMed Web of Science ®Google Scholar
• Calhoun D. A., Li Y., Braylan R. C., Christensen R. D. Assessment of the contribution of the spleen to granulocytopoiesis and erythropoiesis of the mid-gestation human fetus. Early Human Development 1996; 46: 217–227
   PubMed Web of Science ®Google Scholar
• Thiele J., Klein H., Falk S., Bertsch H. P., Fischer R., Stutte H. J. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features. Acta Haematologica 1992; 87: 176–180
   PubMed Web of Science ®Google Scholar
• Douay L., Laporte J. P., Lefrancois G., Najman A., Dupuy-Montbrun M. C., Lopez M., Giarratana M.C, Gorin N. C. Blood and spleen haematopoiesis in patients with myelofibrosis. Leukemia Research 1987; 11: 725–730
   PubMed Web of Science ®Google Scholar
• Mesa R. A., Li C.-Y, Schroeder G., Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood, In press
   Web of Science ®Google Scholar
• Reilly J. T. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Reviews 1997; 11: 233–242
   PubMed Web of Science ®Google Scholar
• Silverstein M. N. The evolution into and the treatment of late stage polycythemia vera. Seminars in Hematology 1976; 13: 79–84
   PubMed Web of Science ®Google Scholar
• Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. British Journal of Haematology 1991; 77: 252–254
   PubMed Web of Science ®Google Scholar
• Elliott M. A., Chen M. G., Silverstein M. N., Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology 1998; 103: 505–511
   PubMed Web of Science ®Google Scholar
• Hickling R. A. Chronic non-leukaemic myelosis. Quarterly Journal of Medicine 1937; 6: 253–275
   Google Scholar
• Bukh H., With T. K. Splenectomy in chronic non-leukemic myeloid splenomegaly with report of a case with osteosclerosis. Acta Chirurgica Scandinavica 1945; 92: 507–532
   Google Scholar
• Green T. W., Conley C. L., Ashbum L. L., Peters H. R. Splenectomy for myeloid metaplasia of the spleen. The New England Journal of Medicine 1953; 248: 211–219
   PubMed Web of Science ®Google Scholar
• Videbaek A. Splenectomy in reticulosis, fibrosis and sclerosis of the bone marrow. Acta Haematologica 1956; 15: 235–245
   PubMedGoogle Scholar
• Jensen M. K. Splenectomy in myelofibrosis. Acta Medico Scandinavica 1964; 175: 533–544
   PubMed Web of Science ®Google Scholar
• Gomes M. R., Silverstein M. N., ReMine W. H. Splenectomy for agnogenic myeloid metaplasia. Surgery, Gynecology & Obstetrics 1967; 125: 106–108
   PubMedGoogle Scholar
• Schwartz S. I., Bernard R. P., Adams J. T., Bauman A. W. Splenectomy for hematologic disorders. Archives of Surgery 1970; 101: 338–347
   PubMed Web of Science ®Google Scholar
• Morgenstern L. Splenectomy for massive splenomegaly due to myeloid metaplasia. American Journal of Surgery 1971; 122: 288–293
   PubMed Web of Science ®Google Scholar
• Milner G. R., Geary C. G., Wadsworth L. D., Doss A. Erythrokinetic studies as a guide to the value of Splenectomy in primary myeloid metaplasia. British Journal of Haematology 1973; 25: 467–484
   PubMed Web of Science ®Google Scholar
• Silverstein M. N., ReMine W. H. Sex, splenectomy, and myeloid metaplasia. JAMA 1974; 227: 424–426
   PubMed Web of Science ®Google Scholar
• Gale D., Sacks P., Lynch S., Bothwell T. H., Bezwoda W., Stevens K. The place of Splenectomy in haematological disorders. South African Medical Journal 1974; 48: 1240–1245
   PubMed Web of Science ®Google Scholar
• Mulder H., Steenbergen J., Haanen C. Clinical course and survival after elective Splenectomy in 19 patients with primary myelofibrosis. British Journal of Haematology 1977; 35: 419–427
   PubMed Web of Science ®Google Scholar
• Cabot E. B., Brennan M. F., Rosenthal D. S., Wilson R. E. Splenectomy in myeloid metaplasia. Annals of Surgery 1978; 187: 24–30
   PubMed Web of Science ®Google Scholar
• Little J. M. A prospective study of 100 splenectomies. The Australian and New Zealand Journal of Surgery 1978; 48: 390–397
   PubMedGoogle Scholar
• Silverstein M. N., ReMine W. H. Splenectomy in myeloid metaplasia. Blood 1979; 53: 515–518
   PubMed Web of Science ®Google Scholar
• Benbassat J., Penchas S., Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. British Journal of Haematology 1979; 42: 207–214
   PubMed Web of Science ®Google Scholar
• Jarvinen H., Kivilaakso E., Ikkala E., Vuopio P., Hastbacka J. Splenectomy for myelofibrosis. Annals of Clinical Research 1982; 14: 66–71
   PubMedGoogle Scholar
• Coon W. W., Liepman M. K. Splenectomy for agnogenic myeloid metaplasia. Surgery, Gynecology & Obstetrics 1982; 154: 561–563
   PubMedGoogle Scholar
• Musser G., Lazar G., Hocking W., Busuttil R. W. Splenectomy for hematologic disease. The UCLA experience with 306 patients. Annals of Surgery 1984; 200: 40–45
   PubMed Web of Science ®Google Scholar
• Sharp P., Grace C. S., Rozenberg M. C., Ham J. M. Splenectomy for massive splenomegaly. The Australian and New Zealand Journal of Surgery 1985; 55: 489–492
   PubMedGoogle Scholar
• Dotevall A., Kutti J., Wadenvik H., Westin J., Angeras U., Darle N. A retrospective analysis of a consecutive series of patients splenectomized for various hematologic disorders. Acta Haematologica 1987; 77: 38–44
   PubMed Web of Science ®Google Scholar
• Benbassat J., Gilon D., Penchas S. The choice between Splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. American Journal of Hematology 1990; 33: 128–135
   PubMed Web of Science ®Google Scholar
• Brenner B., Nagler A., Tatarsky I., Hashmonai M. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Archives of Internal Medicine 1988; 148: 2501–2505
   PubMed Web of Science ®Google Scholar
• Schmitz N., Suttorp M., Schlegelberger B., Weber-Matthiesen K., Tiemann M., Sonnen R. The role of the spleen after bone marrow transplantation for primary myelofibrosis. British Journal of Haematology 1992; 81: 616–618
   PubMed Web of Science ®Google Scholar
• Barosi G., Ambrosetti A., Buratti A., Finelli C., Liberato N. L., Quaglini S., Ricetti M. M., Visani G., Tura S., Ascari E. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7: 200–206
   PubMed Web of Science ®Google Scholar
• Lafaye E, Rain J. D., Clot P., Najean Y. Risks and benefits of Splenectomy in myelofibrosis: an analysis of 39 cases. Nouvelle Revue Française d'Hematologie 1994; 36: 359–362
   PubMedGoogle Scholar
• Jameson J. S., Thomas W. M., Dawson S., Wood J. K., Johnstone J. M. Splenectomy for haematological disease. Journal of the Royal College of Surgeons of Edinburgh 1996; 41: 307–311
   PubMedGoogle Scholar
• Mittelman M., Kyzer S., Zeidman A., Bendayan D., Ramadan E., Cohen A., Cahimoff C. Splenectomy for haematological diseases-a single institution experience. Haematologia 1997; 28: 185–198
   PubMedGoogle Scholar
• Bohner H., Tieier C., Rotzscher V. M., Heit W. Indications for and results of Splenectomy in different hematological disorders. Langenbeck's Archives of Surgery 1997; 382: 79–82
   Google Scholar
• Barosi G., Ambrosetti A., Centra A., Falcone A., Finelli C., Foa P., Grossi A., Guarnone R., Rupoli S., Luciano L., Petti M. C., Pogliani E., Russo D., Ruggeri M., Quaglini S. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid With Myeloid Metaplasia. Blood 1998; 91: 3630–3636
   PubMed Web of Science ®Google Scholar
• Tefferi A., Mesa R. A., Nagorney D. M., Schroeder G., Silverstein M. N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226–2233
   PubMed Web of Science ®Google Scholar
• Jacobs P. Splenectomy and myelofibrosis. South African Medical Journal 1976; 50: 550–551
   PubMed Web of Science ®Google Scholar
• Chaimoff C., Amir J., De Vries A. Splenectomy in myelofibrosis and myeloid metaplasia. Harefuah 1974; 87: 211–212
   PubMed Web of Science ®Google Scholar
• Dechavanne M., Viala J. J., Barbier Y., Revol L. Indications for Splenectomy in the anemic forms of myelofibrosis with myeloid metaplasia of the spleen. La Semaine des Hôpitaux de Paris 1972; 48: 1187–1192
   PubMedGoogle Scholar
• Morgenstern L., Kahn F. H., Weinstein I. M. Subtotal splenectomy in myelofibrosis. Surgery 1966; 60: 336–339
   PubMed Web of Science ®Google Scholar
• McBrine P. A., Miller A., Zimelman A. P., Koff R. S. Polycythemia vera with myelofibrosis and myeloid metaplasia. Acute hepatic failure following splenectomy. American Journal of Clinical Pathology 1980; 74: 693–696
   PubMed Web of Science ®Google Scholar
• Benbassat J., Penchas S. Sex and splenectomy in agnogenic myeloid metaplasia. Acta Haematology 1980; 64: 114–116
   PubMed Web of Science ®Google Scholar
• Benbassat J., Penchas S. “Early” splenectomy and survival in agnogenic myeloid metaplasia. An analysis of 338 cases published since 1940. Acta Haematology 1981; 65: 189–192
   PubMed Web of Science ®Google Scholar
• Schwartz S. I. Splenectomy for hematologic disease. The Surgical Clinics of North America 1981; 61: 117–125
   PubMed Web of Science ®Google Scholar
• Yonemitsu H., Okuda K., Shigeta H., Kondo Y. Splenectomy in primary myelofibrosis: two long-term survivors after splenectomy. Nippon Ketsueki Gakkai Zasshi 1984; 47: 80–88
   PubMedGoogle Scholar
• Kesteven P. J., Pullan J. M., Glass U. H., Wetherley-Mein G. Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders. Clinical and Laboratory Haematology 1985; 7: 297–306
   PubMedGoogle Scholar
• Aviram M., Carter A., Tatarsky I., Levy Y., Brook J. G. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease. Israel Journal of Medical Science 1985; 21: 415–417
   PubMedGoogle Scholar
• Wilson R. E., Rosenthal D. S., Moloney W. C., Osteen R. T. Splenectomy for myeloproliferative disorders. World Journal of Surgery 1985; 9: 431–436
   PubMed Web of Science ®Google Scholar
• Partanen S., Ruutu T., Juvonen E., Pantzar P. Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis. Scandinavian Journal of Haematology 1986; 37: 87–90
   PubMedGoogle Scholar
• Malmaeus J., Akre T., Adami H. O., Hagberg H. Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. British Journal of Surgery 1986; 73: 720–723
   PubMed Web of Science ®Google Scholar
• Coon W. W. Splenectomy for thrombocytopenia due to secondary hypersplenism. Archives of Surgery 1988; 123: 369–371
   PubMed Web of Science ®Google Scholar
• Towell B. L., Levine S. P. Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature. American Journal of Medicine 1987; 82: 371–375
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A., Cervantes K, Bruguera M., Pereira A., Feliu E., Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematologica 1991; 85: 184–188
   PubMed Web of Science ®Google Scholar
• Barosi G., Berzuini C., Liberate L. N., Costa A., Polino G., Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. British Journal of Haematology 1988; 70: 397–401
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Feliu E., Rubio D., Cortes M. T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663
   PubMed Web of Science ®Google Scholar
• Visani G., Finelli C., Castelli U., Petti M. C., Ricci P., Vianelli N., Gianni L., Zuffa E., Aloe Spiriti M. A., Latagliata R., Pileri S., Magrini U., Gugliotta L., Morra E., Bemasconi C., Mandelli F., Tura S. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. British Journal of Haematology 1990; 75: 4–9
   PubMed Web of Science ®Google Scholar
• van Leeuwen F. E., Somers R., Hart A. A. Splenectomy in Hodgkin's disease and second leukaemias. Lancet 1987; 2: 210–211
   PubMedGoogle Scholar
• Tura S., Fiacchini M., Zinzani P. L., Brusamolino E., Gobbi P. G. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. Journal of Clinical Oncology 1993; 11: 925–930
   PubMed Web of Science ®Google Scholar
• Dietrich P. Y, Henry-Amar M., Cosset J. M., Bodis S., Bosq J., Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?. Blood 1994; 84: 1209–1215
   PubMed Web of Science ®Google Scholar
• Socie G., Henry-Amar M., Bacigalupo A., Hows J., Tichelli A., Ljungman P., McCann S. R., Frickhofen N., Van't Veer-Korthof E., Gluckman E. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. The New England Journal of Medicine 1993; 329: 1152–1157
   PubMed Web of Science ®Google Scholar
• Porcu P., Neiman R. S., Orazi A. Splenectomy in agnogenic myeloid metaplasia. Blood 1999; 93: 2132–2134
   PubMed Web of Science ®Google Scholar
• Tefferi A., Silverstein M. N., Li C.-Y. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. British Journal of Haematology 1997; 99: 352–357
   PubMed Web of Science ®Google Scholar
• Tefferi A., Jimenez T, Gray L. A., Mesa R. A., Chen M. G. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. European Journal of Haematology 2001; 66: 37–42
   PubMed Web of Science ®Google Scholar
• Tefferi A., Elliott M. A. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia (letter to editor). Blood 2000; 96: 4007
   PubMed Web of Science ®Google Scholar
• Mesa R. A., Hanson C. A., Rajkumar S. V., Schroeder G., Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374–3380
   PubMed Web of Science ®Google Scholar